Acute reversal of cyclosporine nephrotoxicity by neutral endopeptidase inhibition in stable renal transplant recipients

Transplantation

Volumn 64, Issue 7, 1997, Pages 1007-1017

  Lipkin, Graham W ^a,b,c   Thuraisingham, Raj ^c   Dawnay, Anne B S ^c   Harwood, Steven M ^c   Raine, Anthony E G ^c  

^a Spec Trustees St Bartholomew's H   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATRIAL NATRIURETIC FACTOR; AZATHIOPRINE; CANDOXATRILAT; CYCLOSPORIN A; DIPYRIDAMOLE; ENKEPHALINASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PREDNISOLONE; RANITIDINE; STEROID; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CROSS-OVER STUDIES; CYCLIC GMP; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOSPORINE; DIURESIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPRILYSIN; PROTEASE INHIBITORS; REGIONAL BLOOD FLOW; RENAL CIRCULATION; SODIUM; VASCULAR RESISTANCE;

EID: 0030880348     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00013     Document Type: Article

References (66)

1. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: 5-year follow up of a multicentre trial. Lancet 1987; 2: 506.
2. Fathman CG, Myers BD. Cyclosporin therapy for autoimmune disease. N Engl J Med 1992; 326: 1693.
3. Schachter M. Cyclosporine A and hypertension. J Hypertens 1988; 6: 511.
4. Myers BD. Cyclosporin nephrotoxicity. Kidney Int 1986; 30: 964.
5. Anderson JV, Donkier J, Payne NN, Beacham J, Slater JDH, Bloom SR. Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci 1987; 72: 305.
6. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes preglomerular vasodilatation and postglomerular vasoconstriction in rat kidney. Nature 1986; 342: 473.
7. Janssen WMT, De Zeeuw D, Van der Hem GK, De Jong PE. Antihypertensive effect of a 5 day infusion of atrial natriuretic factor in humans. Hypertension 1989; 13: 640. jannsen
8. Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 1990; 81: 1860.
9. Appel RG, Wang J, Simonson MS, Dunn MJ. A mechanism by which atrial natriuretic factor mediates its glomerular actions. Am J Physiol 1986; 251: F1036.
10. Dieperink H, Leyssac PP, Kemp E, et al. Nephrotoxicity of cyclosporine A in humans: effects on glomerular filtration and tubular reabsorption rates. Eur J Clin Invest 1987; 17: 493.
11. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Transplantation 1987; 44: 135.
12. Pfeilschifter J. Cyclosporin A augments vasoconstrictor-induced rise in intracellular calcium in rat mesangial cells. Biochem Pharmacol 1988; 37: 4205.
13. Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693.
14. Gianello P, Ramboux A, Poelart D, et al. Prevention of acute cyclosporine nephrotoxicity by atrial natriuretic factor after ischaemia in the rat. Transplantation 1989; 47: 512.
15. Capasso G, Rosati C, Ciani F, Giordana DR, Russo F, De Santo NC. The beneficial effect of atrial natriuretic peptide on cyclosporin nephrotoxicity. Am J Hypertens 1990; 3: 204.
16. Lipkin GW, Dawnay ABS, Harwood SM, Kendall RG, Cattell WR, Raine AEG. Renal haemodynamic, hormonal and excretory effects of low-dose atrial natriuretic factor infusion in renal transplant recipients. Clin Sci 1992; 82: 119.
17. Lang CC, Hendeson IS, Macher R, Stewart WK, Struthers AD. Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporin A. J Hypertens 1992; 10: 483.
18. Lang CC, Choy AJ, Pringle TH, et al. Renal, haemodynamic and neurohormonal effects of atrial natriuretic factor in cardiac allograft recipients. Am J Cardiol 1993; 72: 1083.
19. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Si 1990; 47: 1279.
20. Richards M, Espiner E, Frampton C, et al. Inhibition of endopeptidase EC 24.11 in humans: renal and endocrine effects. Hypertension 1990; 16: 269.
21. Jin H, Mattens C, Chen YF, et al. Effect of acute and chronic blockade of neutral endopeptidase with SCH 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. Am J Hypertens 1992; 5: 210.
22. Metcalf MJ, Northridge DB, Henderson E, Jackson N, Dirgie H. Comparison of a new neutral endopeptidase inhibitor with frusemide in left ventricular dysfunction. Br Heart J 1991; 298.
23. Smith WGJ, Dharmasena AD, El Nahas AM, Thoma DM, Coles GA. Short term effect of captopril on renal haemodynamics in chronic renal failure. Nephrol Dial Transplant 1989; 4: 696.
24. Anderson JV, Struthers AD, Payne NN, Slater JOH, Bloom SR. Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man. Clin Sci 1986; 70: 507.
25. Dusterdiek G, McElwee G. estimation of angiotensin II concentration in human plasma by radioimmunoassay: some applications to physiological and clinical states. Eur J Clin Invest 1971; 2: 32.
26. Menard J, Catt K. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin II. Endocrinology 1972; 90: 422.
27. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; ii: 477.
28. Myers BD, Newton L, Boshkos C, et al. Chronic injury to human microvessels with low dose cyclosporine therapy. Transplantation 1988; 46: 694.
29. Stoof TJ, Korstanje MJ, Bilo HJG, Starink TM, Holsmans RFHJ, Donker AJM. Does fish oil protect renal function in cyclosporin-treated psoriasis patients? J Int Med 1989; 226: 437.
30. Chapman JR, Griffiths D, Harding NGL, Morris PJ. Reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet 1985; i: 128.
31. Klintmahn G, Bohman SO, Sundelin B, Wilczek H. Interstitial fibrosis in renal allografts after 12-46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplant period. Lancet 1984: 2: 950.
32. Kiberd BA. Cyclosporine-induced renal dysfunction in human renal allograft recipients. Transplantation 1989; 48: 965.
33. Burke JF, Pirsch JD, Ramos EL, et al. Long term efficacy and safety of cycylosporine in renal transplant recipients. N Engl J Med 1994; 331: 358.
34. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients: a seven year follow up. Transplantation 1990; 50: 589.
35. Curtis JJ, Luke RG, Jones P. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134.
36. Chapman JR, Marcen R, Arias M, Raine AEG, Dunhill MS, Morris PJ. Hypertension after renal transplantation: a comparison of cyclosporine and conventional immunosuppression. Transplantation 1987; 43: 860.
37. Loughran TP, Peeg HJ, Dahlberg S, et al. Incidence of hypertension after marrow transplantation among 112 patients randomised to either cyclosporin or methotrexate as graft versus host disease prophylaxis. Br J Haematol 1985; 59: 547.
38. Palestine AG, Austin HA, Balow JE , et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293.
39. Weidmann P, Hasler L, Gnadinger MP, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986; 77: 734.
40. Maack T, Suzuki M, Almeida FP, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675.
41. Stephenson SL, Kenny AJ. Metabolism of neuropeptides: hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J 1987; 241: 237.
42. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87.
43. Northridge DB, Jardine AG, Alabaster CT, et al. Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 1989; 2: 591.
44. O'Connell JE, Jardine AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992; 10: 271.
45. Dussaule JC, Michel C, Peraldi MN, et al. Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure. Clin Sci 1993; 84: 31.
46. Chui PJS, Tetzloff G, Romano MT, Foster CJ, Sybertz EJ. influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am J Physiol 1991; 260: R208.
47. Wong KR, Xie MH, Shi LB, et al. Urinary cGMP as a marker of renal activity of atrial natriuretic factor. Am J Physiol 1988; 225: F1220.
48. Lipkin GW, Dawnay ABS, Harwood SM, Jackson NC, Cattell WR, Raine AEG. Enhanced natriuretic effect of acute neutral endopeptidase inhibition in patients with chronic renal failure [Abstract]. J Am Soc Nephrol 1992; 3: 440.
49. Thompson SC, Tucker BJ, Gabbai F, Blantz RC. Functional effects on glomerular haemodynamics of short-term chronic cyclosporine in male rats. J Clin Invest 1989; 83: 960.
50. Lipkin GW, Dawnay ABS, Cattell WR, Raine AEG. chronic neutral endopeptidase inhibition ameliorates experimental cyclosporin nephrotoxicity. Proc Int Soc Nephrol 1993.
51. Ura N, Carretero OA, Erdös EG. Role of neutral endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987; 32: 507.
52. Lang CC, Motwani JG, Coutie W, Struthers AD. Influence of candoxatril on plasma brain natriuretic peptide in heart failure [Letter]. Lancet 1991; iii: 225.
53. Kenny A, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase 24.11. J Biochem 1993; 291: 83.
54. Ziegler MG, Morrissey EC, Kennedy B, Elayan H. Sources of urinary catecholamines in renal dennervated transplant recipients. J Hypertens 1990; 8: 927.
55. Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Drechsler S, Kramer HJ. Cellular signalling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide. Clin Invest 1993; 71: 153.
56. Raine AEG, Anderson JV, Bloom SR, Morris PJ. Plasma atrial natriuretic factor and graft function in renal transplant recipients. Transplantation 1989; 48: 796.
57. Wilkins MR, Unwin RJ, Kenny J. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993; 43: 273.
58. Greenwald JE, Needleman P, Wilkins MR, Schreiner GF. Renal synthesis of an atriopeptin-like protein in physiology and pathophysiology. Am J Physiol 1991; 260: F602.
59. Bantle JP, Bourdreau RT, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83: 59.
60. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990; 70: 665.
61. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram HI, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992; 71: 1501.
62. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993; 11: 407.
63. Ishii M, Hirata Y, Sugimoto T, Matsuoka H, Kimura K, Ishimitsu T, et al. Effect of human atrial natriuretic peptide on proteinuria in patients with primary glomerular diseases. Clin Sci 1989; 77: 643.
64. Hirata Y, Ishii M, Fukui K, et al. Differential effects of atrial natriuretic peptide and dopamine on urinary protein excretion in chronic glomerulonephritis. Clin Sci 1991; 80: 131.
65. Brenner BM, Dworkin LD, Ichikawa I. Glomerular ultrafiltration. In: Brenner BM, Rector FC, eds. The kidney. Philadelphia: WB Saunders, 1981: 124.
66. Walser M. Weighted least squares regression analysis of factors contributing to the progression of chronic renal failure. Contrib Nephrol 1989; 75: 127.